Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Single and combined effects of Δ9 -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain.

King KM, Myers AM, Soroka-Monzo AJ, Tuma RF, Tallarida RJ, Walker EA, Ward SJ.

Br J Pharmacol. 2017 Sep;174(17):2832-2841. doi: 10.1111/bph.13887. Epub 2017 Jul 27.

2.

Drug Combinations: Tests and Analysis with Isoboles.

Tallarida RJ.

Curr Protoc Pharmacol. 2016 Mar 18;72:9.19.1-19. doi: 10.1002/0471141755.ph0919s72.

3.

Levamisole enhances the rewarding and locomotor-activating effects of cocaine in rats.

Tallarida CS, Tallarida RJ, Rawls SM.

Drug Alcohol Depend. 2015 Apr 1;149:145-50. doi: 10.1016/j.drugalcdep.2015.01.035. Epub 2015 Feb 7.

4.

Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice.

Neelakantan H, Tallarida RJ, Reichenbach ZW, Tuma RF, Ward SJ, Walker EA.

Behav Pharmacol. 2015 Apr;26(3):304-14. doi: 10.1097/FBP.0000000000000119.

PMID:
25485642
5.

Ethanol and cocaine: environmental place conditioning, stereotypy, and synergism in planarians.

Tallarida CS, Bires K, Avershal J, Tallarida RJ, Seo S, Rawls SM.

Alcohol. 2014 Sep;48(6):579-86. doi: 10.1016/j.alcohol.2014.07.006. Epub 2014 Aug 7.

6.

Combining opioid and adrenergic mechanisms for chronic pain.

Smith HS, Raffa RB, Pergolizzi JV, Taylor R, Tallarida RJ.

Postgrad Med. 2014 Jul;126(4):98-114. doi: 10.3810/pgm.2014.07.2788. Review.

PMID:
25141248
7.

Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit.

Cowan A, Raffa RB, Tallarida CS, Tallarida RJ, Christoph T, Schröder W, Tzschentke TM.

Eur J Pain. 2014 Sep;18(8):1148-56. doi: 10.1002/j.1532-2149.2014.00461.x. Epub 2014 Feb 26.

PMID:
24574066
8.

Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine's action in vivo.

Tallarida CS, Egan E, Alejo GD, Raffa R, Tallarida RJ, Rawls SM.

Neuropharmacology. 2014 Apr;79:590-5. doi: 10.1016/j.neuropharm.2014.01.002. Epub 2014 Jan 15.

9.

Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.

Christoph T, Schröder W, Tallarida RJ, De Vry J, Tzschentke TM.

J Pharmacol Exp Ther. 2013 Dec;347(3):794-801. doi: 10.1124/jpet.113.207704. Epub 2013 Sep 19.

10.

Methylphenidate and impulsivity: a comparison of effects of methylphenidate enantiomers on delay discounting in rats.

Slezak JM, Ricaurte GA, Tallarida RJ, Katz JL.

Psychopharmacology (Berl). 2014 Jan;231(1):191-8. doi: 10.1007/s00213-013-3220-8. Epub 2013 Aug 24.

PMID:
23975034
11.

A search for interaction among combinations of drugs of abuse and the use of isobolographic analysis.

Tallarida RJ, Midic U, Lamarre NS, Obradovic Z.

J Clin Pharm Ther. 2013 Jun;38(3):190-5. doi: 10.1111/jcpt.12055. Epub 2013 Apr 3.

PMID:
23550787
12.

Cocaine synergism with α agonists in rat aorta: computational analysis reveals an action beyond reuptake inhibition.

Lamarre NS, Raffa RB, Tallarida RJ.

Drug Alcohol Depend. 2013 May 1;129(3):226-31. doi: 10.1016/j.drugalcdep.2012.11.020. Epub 2012 Dec 25.

13.

Quantitative methods for assessing drug synergism.

Tallarida RJ.

Genes Cancer. 2011 Nov;2(11):1003-8. doi: 10.1177/1947601912440575.

14.

Revisiting the isobole and related quantitative methods for assessing drug synergism.

Tallarida RJ.

J Pharmacol Exp Ther. 2012 Jul;342(1):2-8. doi: 10.1124/jpet.112.193474. Epub 2012 Apr 17. Review.

15.

Fixed-dose combinations for emerging treatment of pain.

Raffa RB, Tallarida RJ, Taylor R Jr, Pergolizzi JV Jr.

Expert Opin Pharmacother. 2012 Jun;13(9):1261-70. doi: 10.1517/14656566.2012.668531. Epub 2012 Mar 16. Review.

PMID:
22420908
16.

Mephedrone ("bath salt") pharmacology: insights from invertebrates.

Ramoz L, Lodi S, Bhatt P, Reitz AB, Tallarida C, Tallarida RJ, Raffa RB, Rawls SM.

Neuroscience. 2012 Apr 19;208:79-84. doi: 10.1016/j.neuroscience.2012.01.019. Epub 2012 Jan 20.

17.

'Null method' determination of drug biophase concentration.

Tallarida RJ, Lamarre N, Raffa RB.

Pharm Res. 2012 Mar;29(3):637-42. doi: 10.1007/s11095-011-0612-5. Epub 2011 Oct 29.

18.

On the quantitation of an agonist with dual but opposing components of action: application to vascular endothelial relaxation.

Lamarre NS, Parry T, Tallarida RJ.

Eur J Pharmacol. 2011 Nov 16;670(1):204-7. doi: 10.1016/j.ejphar.2011.08.007. Epub 2011 Sep 2.

19.

Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain.

Christoph T, De Vry J, Schiene K, Tallarida RJ, Tzschentke TM.

Eur J Pharmacol. 2011 Sep;666(1-3):72-9. doi: 10.1016/j.ejphar.2011.05.029. Epub 2011 May 27.

PMID:
21640095
20.

Resveratrol in combination with other dietary polyphenols concomitantly enhances antiproliferation and UGT1A1 induction in Caco-2 cells.

Iwuchukwu OF, Tallarida RJ, Nagar S.

Life Sci. 2011 Jun 6;88(23-24):1047-54. doi: 10.1016/j.lfs.2011.03.016. Epub 2011 Apr 3.

21.

Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.

Schröder W, Tzschentke TM, Terlinden R, De Vry J, Jahnel U, Christoph T, Tallarida RJ.

J Pharmacol Exp Ther. 2011 Apr;337(1):312-20. doi: 10.1124/jpet.110.175042. Epub 2011 Jan 24. Erratum in: J Pharmacol Exp Ther. 2012 Jul;342(1):232. J Pharmacol Exp Ther. 2014 Mar;348(3):489.

22.

Midazolam enhances the analgesic properties of dexmedetomidine in the rat.

Boehm CA, Carney EL, Tallarida RJ, Wilson RP.

Vet Anaesth Analg. 2010 Nov;37(6):550-6. doi: 10.1111/j.1467-2995.2010.00565.x.

23.

Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

Raffa RB, Tallarida RJ.

J Clin Pharm Ther. 2010 Jun;35(3):249-55. doi: 10.1111/j.1365-2710.2009.01086.x.

24.

Future directions.

Raffa RB, Tallarida RJ.

Adv Exp Med Biol. 2010;678:165-7.

PMID:
20738019
25.

Combination analysis.

Tallarida RJ.

Adv Exp Med Biol. 2010;678:133-7. Review.

PMID:
20738015
26.

Chemo fog: cancer chemotherapy-related cognitive impairment. Preface.

Raffa RB, Tallarida RJ.

Adv Exp Med Biol. 2010;678:vii-viii. No abstract available.

PMID:
20737998
27.

Oxycodone combinations for pain relief.

Raffa RB, Pergolizzi JV, Segarnick DJ, Tallarida RJ.

Drugs Today (Barc). 2010 Jun;46(6):379-98. doi: 10.1358/dot.2010.46.6.1470106. Review.

28.

The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations.

Tallarida RJ, Raffa RB.

Pharmacol Ther. 2010 Aug;127(2):165-74. doi: 10.1016/j.pharmthera.2010.04.011. Epub 2010 May 28. Review.

29.

Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in mice.

Miller JS, Tallarida RJ, Unterwald EM.

Brain Res Bull. 2010 May 31;82(3-4):184-7. doi: 10.1016/j.brainresbull.2010.03.005. Epub 2010 Mar 25.

30.

The determination and application of fixed-dose analgesic combinations for treating multimodal pain.

Raffa RB, Pergolizzi JV Jr, Tallarida RJ.

J Pain. 2010 Aug;11(8):701-9. doi: 10.1016/j.jpain.2009.12.010. Epub 2010 Mar 24. Review.

31.

Comparison of human and porcine gastric clasp and sling fiber contraction by M2 and M3 muscarinic receptors.

Vegesna AK, Braverman AS, Miller LS, Tallarida RJ, Tiwana MI, Khayyam U, Ruggieri MR Sr.

Am J Physiol Gastrointest Liver Physiol. 2010 Apr;298(4):G530-4. doi: 10.1152/ajpgi.00129.2009. Epub 2010 Feb 4.

32.

On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data.

Tallarida RJ, Cowan A, Raffa RB.

Drug Alcohol Depend. 2010 Jun 1;109(1-3):126-9. doi: 10.1016/j.drugalcdep.2009.12.014. Epub 2010 Jan 12.

33.

Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity.

Tanda G, Newman AH, Ebbs AL, Tronci V, Green JL, Tallarida RJ, Katz JL.

J Pharmacol Exp Ther. 2009 Sep;330(3):802-9. doi: 10.1124/jpet.109.154302. Epub 2009 May 29.

34.

Cocaine-induced hyperactivity and sensitization are dependent on GSK3.

Miller JS, Tallarida RJ, Unterwald EM.

Neuropharmacology. 2009 Jun;56(8):1116-23. doi: 10.1016/j.neuropharm.2009.03.006. Epub 2009 Mar 27.

35.

Quantitation of the contractile response mediated by two receptors: M2 and M3 muscarinic receptor-mediated contractions of human gastroesophageal smooth muscle.

Braverman AS, Miller LS, Vegesna AK, Tiwana MI, Tallarida RJ, Ruggieri MR Sr.

J Pharmacol Exp Ther. 2009 Apr;329(1):218-24. doi: 10.1124/jpet.108.148106. Epub 2009 Jan 6.

36.

A quantitative study to assess synergistic interactions between urotensin II and angiotensin II.

Lamarre NS, Tallarida RJ.

Eur J Pharmacol. 2008 May 31;586(1-3):350-1. doi: 10.1016/j.ejphar.2008.02.071. Epub 2008 Feb 29.

PMID:
18371948
37.

The use of occupation isoboles for analysis of a response mediated by two receptors: M2 and M3 muscarinic receptor subtype-induced mouse stomach contractions.

Braverman AS, Tallarida RJ, Ruggieri MR Sr.

J Pharmacol Exp Ther. 2008 Jun;325(3):954-60. doi: 10.1124/jpet.108.137018. Epub 2008 Mar 13.

38.

Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice.

Ward SJ, Lefever TW, Jackson C, Tallarida RJ, Walker EA.

J Pharmacol Exp Ther. 2008 May;325(2):567-76. doi: 10.1124/jpet.107.131771. Epub 2008 Feb 6.

39.

Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia.

Codd EE, Martinez RP, Molino L, Rogers KE, Stone DJ, Tallarida RJ.

Pain. 2008 Feb;134(3):254-62. Epub 2007 May 25.

PMID:
17532139
40.

Intra-VTA CART 55-102 reduces the locomotor effect of systemic cocaine in rats: an isobolographic analysis.

Jaworski JN, Kimmel HL, Mitrano DA, Tallarida RJ, Kuhar MJ.

Neuropeptides. 2007 Apr;41(2):65-72. Epub 2007 Feb 7.

41.

A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide.

Benamar K, Yondorf M, Meissler JJ, Geller EB, Tallarida RJ, Eisenstein TK, Adler MW.

J Pharmacol Exp Ther. 2007 Mar;320(3):1127-33. Epub 2006 Dec 28.

42.

Nonlinear isobologram and superadditive withdrawal from cocaine: cannabinoid combinations in planarians.

Raffa RB, Stagliano GW, Tallarida RJ.

Eur J Pharmacol. 2007 Feb 5;556(1-3):89-90. Epub 2006 Oct 27.

43.

Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy.

Rawls SM, Tallarida RJ, Zisk J.

Eur J Pharmacol. 2006 Dec 28;553(1-3):89-98. Epub 2006 Aug 26.

PMID:
17109846
44.

Interactions between drugs and occupied receptors.

Tallarida RJ.

Pharmacol Ther. 2007 Jan;113(1):197-209. Epub 2006 Sep 7. Review.

45.

Modified 'Joyce model' of opioid dependence/withdrawal.

Raffa RB, Tallarida RJ.

Eur J Pharmacol. 2006 Dec 3;551(1-3):54-7. Epub 2006 Sep 16.

46.

Subadditive withdrawal from cocaine/kappa-opioid agonist combinations in Planaria.

Raffa RB, Stagliano GW, Tallarida RJ.

Brain Res. 2006 Oct 9;1114(1):31-5. Epub 2006 Aug 17.

PMID:
16914122
47.

Schild (apparent pA2) analysis of a kappa-opioid antagonist in Planaria.

Raffa RB, Baron DA, Tallarida RJ.

Eur J Pharmacol. 2006 Jul 1;540(1-3):200-1. Epub 2006 May 3.

PMID:
16737694
48.

An overview of drug combination analysis with isobolograms.

Tallarida RJ.

J Pharmacol Exp Ther. 2006 Oct;319(1):1-7. Epub 2006 May 2.

49.

Effects of drug combinations on smooth muscle cell proliferation: an isobolographic analysis.

Parry TJ, Thyagarajan R, Argentieri D, Falotico R, Siekierka J, Tallarida RJ.

Eur J Pharmacol. 2006 Feb 17;532(1-2):38-43. Epub 2006 Jan 30.

PMID:
16448648
50.

The dynamic relationship between mu and kappa opioid receptors in body temperature regulation.

Chen X, McClatchy DB, Geller EB, Tallarida RJ, Adler MW.

Life Sci. 2005 Dec 12;78(4):329-33. Epub 2005 Oct 28.

PMID:
16257420

Supplemental Content

Loading ...
Support Center